Amgen/J&J Procrit arbitration
Executive Summary
Johnson & Johnson will retain license to sell Procrit (epoetin alfa) in the U.S. following Oct. 18 decision by an arbitration panel, but will pay Amgen $150 mil. in damages. J&J is seeking attorneys' fees. Amgen argued that J&J intentionally sold Procrit in Amgen's exclusive dialysis market, violating a 1985 agreement between the companies. Amgen sells epoetin alfa as Epogen for dialysis patients, while J&J sells Procrit in non-dialysis markets (1"The Pink Sheet" March 20, 2000, p. 19)...
You may also be interested in...
Amgen Effort To Reclaim Procrit Rights From J&J Moving To Trial Phase
Amgen will receive a trial in its arbitration claim seeking to terminate Johnson & Johnson's license to sell Procrit in the U.S., but appears to have a difficult burden to meet before the arbitration panel.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.